HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 08, August 2019 – Digitalization vs Digitization — Exploring Emerging Trends in Healthcare       » Shanghai neurologists test brain implant to tackle drug addiction       » Gene-editing researchers reduce cancer risk       » Artificial Intelligence in Precision Cancer Diagnostics: Myth or Magic?       » Healing with Technology       » Smart Hospital: An Instrument of Care       » Transforming Healthcare with Data and Artificial Intelligence      
EYE ON CHINA
Valsartan manufactured by Chinese company recalled over cancer risks
Made in China heart drug has been recalled across the country for presence of contaminant N-nitrosodimethylamine

In the latest medical safety scandal to hit China, the National Health Commission (NHC) has asked all medical institutions to stop using medicines containing the active ingredient valsartan produced by a domestic pharmaceutical company and to assist with related recalls.

The recall is due to an impurity involving the contaminant N-nitrosodimethylamine (NDMA), which was detected in the active pharmaceutical ingredients for valsartan, used to treat high blood pressure and heart failure. NDMA has been linked to cancer.

Medical institutions must not use the recalled drugs containing impurity-affected valsartan during diagnosis and treatment, said a statement by the NHC, which added that medical personnel should take efficient measures to ensure medical safety.

The statement also asked medical institutions to keep local medical authorities and regulators informed about their work on assisting with the recall and halting use of the recalled drugs.

The producer, Zhejiang Huahai Pharmaceutical Co. Ltd., halted shipments and launched voluntary recalls in domestic and foreign markets after it reported discovery of NDMA traces in its products for export to the drug regulator on 6 July 2018.

Source: Xinhua

Click here for the complete issue.

NEWS CRUNCH  
news How blockchain can save the food industry millions from recalls
news China Healthcare and Pharma Digital Innovation Summit
news BIO-PHARM2019 — The Most Influential Forum in China's Biopharm Industry
news The rise of personalised nutrition
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy